Tali Digital: A $0.05 Micro-Cap Pivots to Computing, Dilution Is the Real Story

Tali Digital, an Australian digital health company with a market capitalization of roughly A$4.21 million, has lodged an application with the Australian Securities Exchange to quote 7,009,121 new shares. That filing is not an isolated capital raise. It is Tranche 1 of a broader A$3.3 million equity offering tied to the company's acquisition of Datasphere Analytics — a transaction that would expand Tali's share base by more than 100 percent, pivot the company into memristive computing, and leave existing shareholders holding a much smaller slice of a much more speculative business.

The shares are being issued at A$0.05 each, raising A$350,456. If the full two-tranche placement and the acquisition close as planned, another 65 million shares hit the market: 42,990,879 in Tranche 2 and up to 10 million more through a share purchase plan offered to existing holders, plus 22 million as acquisition consideration for Datasphere. Against a pre-deal share count of roughly 46.73 million, that is dilution approaching 70 percent.

That number is the anchor of this situation. Everything else — the technology promise, the strategic rationale, the directors subscribing for up to A$360,000 of their own capital — matters only to the extent that it justifies creating enough new equity to wipe out the majority of what current owners hold.

What Tali Digital Actually Is

Before the pivot, Tali Digital was a digital therapeutic company selling cognitive training programs for children aged 3 to 10. Its flagship product, ReadyAttentionGo!, is an app-based program designed to improve attention skills. It operates alongside a social-emotional learning platform called You Can Do It! Education, which Tali acquired in June 2025.

The financial reality of this business is stark. For the fiscal year ending June 2026, total revenue came to A$286,744, a 415.8 percent increase over the prior year, but only because the base was roughly A$56,000. The company lost A$2.21 million for the full year, tripling the prior year's A$660,624 loss. The loss spike was driven largely by an A$1.34 million impairment of the You Can Do It! intangible assets — written down less than a year after Tali bought them.

Net tangible assets per share stood at 1.38 cents as of June 2026, down from 1.89 cents the prior year. Deferred income of A$189,499 suggests some subscription receipts ahead of service delivery, but in the half year ended December 2025, management noted subscription sales were "slightly below internal expectations". The company raised prices in early 2026 in hopes of supporting revenue growth, but the operating trajectory showed a business that could not scale its way to profitability with its existing products.

The Datasphere Pivot

On August 21, 2026, Tali announced a binding agreement to acquire 100 percent of Datasphere Analytics through the issue of 22 million shares at a deemed issue price of A$0.05. The strategic rationale is not to buy a revenue stream. Datasphere generates no revenue. It is a vehicle that holds an option to negotiate an exclusive worldwide license for memristive in-memory computing technology developed at Technion, Israel's premier engineering university.

Memristive computing, in brief, performs logic operations directly within the memory array rather than shuttling data between memory and processor. In theory, the architecture offers advantages for parallel computing, large-scale databases, and privacy-sensitive data processing. Tali's pitch centers on "blind" analysis — processing sensitive education and health data within a controlled environment without external transfers.

The technology is at an early research stage. It has not been demonstrated at commercial scale. No definitive license with Technion exists. The chain of events required before this technology becomes a product, let alone a revenue line, is long and conditional.

Datasphere must raise US$650,000 in qualifying financing by October 3, 2026 — just five weeks away — to exercise its option on the Technion IP. After exercising the option, it has 180 days to finalize a license agreement. Post-license, Datasphere must raise US$1 million within 18 months and US$1.35 million within 36 months. Technion takes 30 percent of the consideration payable to Datasphere shareholders, plus royalties of 2 percent on net product sales and 20 percent on sublicensing fees. Datasphere also owes Technion approximately NIS 579,177 in past patent costs.

Tali's planned use of the A$3.3 million raise allocates A$920,000 toward meeting the US$650,000 qualifying financing deadline and A$580,000 for due diligence and integration. The remainder supports the existing health product line, sales, marketing, and working capital.

What This Means for Current Shareholders

The arithmetic of this transaction is what investors need to understand. Before the deal, Tali had roughly 47 million shares outstanding and a market capitalization near A$4 million. After the full transaction — placement shares, acquisition shares, and the potential share purchase plan — the company could have as many as 135 million shares. Even if the share purchase plan is not fully taken up, the share count could still more than double.

At the current share price of A$0.05, Tali is trading at its net tangible asset value of 1.38 cents on a pre-dilution basis. Post-dilution, that figure drops further. The A$3.3 million raise sounds substantial, but spread across 135 million shares, it works out to roughly 2.5 cents of new cash per share. Against a company that burned A$2.21 million in a single year, that runway is thin.

The directors intend to subscribe for up to 7.2 million shares and 2.4 million options at A$0.05, representing up to A$360,000. That is a meaningful skin-in-the-game signal for a micro-cap, and it should be noted. But directors also benefit if the option strike of A$0.15 becomes achievable through a speculative re-rating, even if the company's underlying economics remain fragile.

The Honest Read

Tali Digital is not the kind of stock most U.S. investors can access — it trades on the Australian Securities Exchange, far below the typical threshold for American depositary receipts. But the pattern it illustrates is a common one in the micro-cap space, and it deserves attention for what it teaches about how to read a dilution event.

This is not a company raising capital to fund a business that already works at a higher volume. This is a company with A$286,000 in annual revenue and a two-million-dollar annual loss that has decided its existing products are not the answer and is issuing more than double its current share base to pursue a computing technology that is years from any commercial outcome. The dilution is not a cost of growth. It is the price of a pivot.

There is a version where this works. The Technion technology proves commercially viable. Tali secures the license, raises the subsequent funding rounds, and the memristive computing platform becomes a defensible asset. The existing health business stabilizes as a cash cover while the technology matures. That is a multi-year, multi-round path with several points of failure along the way.

There is also the more likely version where the October 3 financing deadline is not met, the license option lapses, Datasphere has no standalone value, and Tali is left with a massively diluted share base and no new growth engine. The existing health business — which was already losing money before the pivot — continues to burn through whatever cash the raise provides.

The Clock

The shareholder meeting is September 25. The deal targets completion on September 29. The October 3 Technion financing deadline follows. These are not distant catalysts — they are this month.

For anyone holding or watching Tali Digital, the question is not whether the memristive technology sounds promising. It is whether a company with sub-A$300,000 revenue, a A$2.2 million annual loss, and net tangible assets of 1.38 cents per share is the right vehicle to carry a speculative computing technology from research to commercialization. The A$0.05 share price already prices this as a high-risk micro-cap. The dilution makes it a higher-risk micro-cap with a longer road to anything resembling profitability.